Stock Ideas – Morning Updates | Glenmark Life Sciences IPO | Stock in News | Hindi | 27th July

In this video, we have spoken about Market Outlook for the Day. Watch this video to know more.

#premarketnews #5paisamorningcuppa #stockideas #glenmarklifesciences #ipo #fii #dii

Nifty Outlook:
Nifty finds important support around 15750 while 15900 will act as resistance.

Bank Nifty:
Bank Nifty finds support around 34 while 34650 will act as resistance.

Stock Ideas:
Cash Intraday- BUY VBL AT 752 SL 742 TGT 762
Derivative Future Call Intraday- BUY ACC FUT AT 2376 SL 2360 TGT 2395.

Stocks in News:
1. Sun Pharma
2. IndusInd bank
3. ONGC
Sun Pharma: Sun Pharma has entered a licensing and supply pact with Cassiopea SpA, an Italian specialty drugmaker, to market the acne cream Winlevi in the USA and Canada.

IndusInd Bank: IndusInd Bank’s board gave the nod to raise up to Rs. 30,000 crores through a mix of debt and equity.

ONGC: ONGC startup fund has invested in a seed round of Pepfuels – a startup focused on door-step fuel delivery space.

Results today:
Some of the results are Dr Reddy’s, Indusind Bank, Interglobe Aviation, Torrent Pharma, Dalmia Bharat, Dixon Technologies, The Ramco Cements, Canara Bank and Sanofi India.

IPO Update:
Glenmark Life Sciences’ Rs 1,514 crore initial public offering (IPO) opens for subscription today, July 27. Investors can bid for Glenmark Life Sciences IPO at the fixed price band of Rs 695 – 720 per share in a bid lot of 20 shares.

FII and DII data:
Foreign institutional investors (FIIs) net sold shares worth Rs 2,376.79crore, while domestic institutional investors (DIIs) net purchased shares worth Rs 1,551.27crore in the Indian equity market on July 26, as per provisional data available on the NSE

Hit the 🔔 to get notified whenever we post a new video on Market Outlook

To register, visit:

✔️To invest in IPOs Open a Demat Account with 5paisa:
✔️Simply 📱 Download 5paisa Trading App:

For more information, visit our website:
Stay socially connected with us, Join us on:
Telegram:
Instagram:
Twitter:
LinkedIn:
Facebook: